Kiniksa Pharmaceuticals (NASDAQ: KNSA) — Perfil da empresa, notícias e dados financeiros
Kiniksa Pharmaceuticals is a biopharmaceutical company dedicated to developing treatments for diseases with unmet medical needs.
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals (NASDAQ:KNSA) is a biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with significant unmet medical needs. The company's pipeline includes a range of candidates in various stages of development targeted at inflammatory and autoimmune diseases, among others. With a commitment to improving patient outcomes, Kiniksa aims to advance its portfolio through rigorous scientific research and clinical trials. Its strategic objectives center on bringing novel therapies to market and expanding its reach to address conditions with high demand for treatment options.
Resumo
Operações
Produtos e/ou serviços de Kiniksa Pharmaceuticals
- Arcalyst (rilonacept), a treatment for recurrent pericarditis offering long-term disease control.
- Mavrilimumab, an investigational fully human monoclonal antibody for the treatment of giant cell arteritis.
- KPL-716 (vixarelimab), targeting pruritic diseases by blocking oncostatin M receptor beta.
- KPL-404, a novel therapy aiming to disrupt T cell-dependent B cell maturation in autoimmune diseases.
- Rilonacept for the treatment of a range of inflammatory diseases, demonstrating significant potential in reducing symptoms.
- KPL-0454, a next-generation anti-inflammatory treatment targeting NLRP3 inflammasome for various conditions.
equipe executiva do Kiniksa Pharmaceuticals
- Sanjiv K. PatelCEO & Chairman of the Board
- Mark A. RagosaExecutive VP & CFO
- Ross Michael MoatExecutive VP, COO & Principal Operating Officer
- John F. PaoliniExecutive VP & Chief Medical Officer
- Eben TessariConsultant
- Michael R. MegnaSenior VP & Chief Accounting Officer
- Mei JangSenior VP & Chief Technical Officer
- Jonathan KirshenbaumInvestor Relations Officer
- Douglas J. BarrySenior VP, Chief Legal Officer & Secretary
- Martina StruckSenior VP & Chief Regulatory Officer
Principais indicadores financeiros
Resultados divulgados pela Kiniksa Pharmaceuticals, em USD.
- Cap. de mercado
- 6,9 bi
- Receita (TTM)
- 840,8 mi
- P/L
- 90.1
- LPA (diluído, TTM)
- 1.0
- Dividend yield
- —
- Margem de lucro
- 9.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 677,6 mi | 77,2 mi | 59 mi | |
| 423,2 mi | -45,6 mi | -43,2 mi | |
| 270,3 mi | -25,2 mi | 14,1 mi | |
| 220,2 mi | 9,8 mi | 183,4 mi |